Update on the Management of Diabetic Kidney Disease

Diabetic kidney disease (DKD) is a complication that occurs in approximately 40% of patients with type 2 diabetes. DKD is associated with significant morbidity and mortality and, additionally, complicates glycemic management. While interventions to prevent and/or slow the progression of DKD have historically been limited, agents from the sodium-glucose cotransporter-2 inhibitor, glucagon-like peptide-1 receptor agonist, and nonsteroidal mineralocorticoid receptor antagonist classes of medication offer new hope for DKD patients. Pharmacists can play a critical role as members of the care team to promote the safe and appropriate use of these kidney-protective agents in appropriate individuals to improve patient outcomes.